AYURCANN REPORTS RECORD SALES IN Q1 2024 FEATURING A 249% INCREASE IN GROSS REVENUE - Seite 3

Future strategies and moving forward.

Ayurcann believes that our quality, brands, and product offerings will drive growth. Price compression has affected all categories in the industry and price compression is being driven by the financial issues faced by many competitors. As companies leave the sector, the demand for products is still maintained in the marketplace. As a business focused on the quality and value, we have seen the market growth and demand for our products being translated to a strong position for Ayurcann.

“We feel that the awareness of our brands in the market and the quality and flavour profile we are introducing will enable Ayurcann to gain market share quickly. Offering value and potency in a segment that is primed to grow even more”. Said Igal Sudman, Chief Executive Officer.

For further information, please contact:
Igal Sudman, Chairman and Chief Executive Officer
Ayurcann Holdings Corp.
Tel: [phone]
Email: [e-mail]

Investor Relations:

Email: [e-mail]

About Ayurcann:

Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada.

For more information about Ayurcann, please visit www.ayurcann.com and its profile page on SEDAR+ at www.sedarplus.ca.

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “strategy”, “expects” or “does not expect”, “intends”, “continues”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “will be taken”, “will launch” or “will be launching”, “will include”, “will allow”, “will be made” “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company’s plans to produce various derivative cannabis products; the Company’s focus on custom processes and pharma grade products for the adult use and medical cannabis industry in Canada; the Company’s focus on maximizing its margins and market share; the Company continued search for new opportunities to increase its revenues, through launches of new products under its existing brands and without significant increases to overhead costs; the Company’s securing of the stated SKUs and number of anticipated SKUs launches under the provided timelines, including the plans to introduce 4 infused pre-rolls SKUs in the second fiscal quarter and an additional 4 infused pre-roll SKUs in the third fiscal quarter; the Company’s plans to reduce cost through increased efficiency in its internal processes and partnerships; conclusions based on the quoted market studies, including, infused pre-rolls becoming the favorite consumer product, pre-rolls being the fastest-growing product segment in the industry, and that the average cannabis consumer is looking for fast-acting and high-potency pre-roll products; the Company’s belief that people make a good company and how the Company intends to reward and retain its personnel; the Company’s stated plans to sustain and grow its market share, including, the increasing of the awareness the Company’s brands, the quality and flavour profile of its products, offering value and potency; and the Company’s plans to enhance its product development capabilities by differentiating its products with its competitors.